医薬品市場規模・シェア・動向分析レポート：分子タイプ別、製品タイプ別、疾患別、年齢層別、投与経路別、流通チャネル別、地域別、セグメント動向、2025～2030年

医薬品市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の医薬品市場規模は2030年までに2兆3,504億3,000万米ドルに達すると推定され、2025～2030年にかけて6.12%のCAGRで成長する見込みです。

医薬品市場の成長は、慢性疾患の有病率が増加し、新規治療の開発ニーズが高まっていることに起因しています。National Council on Agingによると、高齢者の約95％が少なくとも1つの慢性疾患を抱えており、約80％が2つ以上の慢性疾患を抱えていると推定されています。さらに、糖尿病、関節炎、心臓病などの慢性疾患は、高齢者に不釣り合いに影響を与えています。

予防、早期発見、重点的な治療、効果的な治療のためには、意識が重要です。病気やその症状を自覚している人は、検診や検査、健康診断といった予防措置を取る傾向が強いです。様々な病気に対する意識の高まりも、医薬品セグメントを牽引する要素です。がんや糖尿病といった病気について人々が認識するようになったことで、それらの病気を発症した場合に治療を受ける可能性が高まっています。公的機関や民間団体が、国民に意識を広め、教育するために、さまざまな取り組みを行っています。さらに、多くの人々が処方薬費用をカバーする保険に加入するようになり、医薬品需要の増加に寄与しています。

さらに、新規治療の開発における技術の進歩により、医薬品需要は世界的に大幅に増加しています。製薬産業は、研究開発だけでなく、製品の販売や流通にもかつてない勢いで投資しています。この産業は、人々の健康に明確かつ直接的に取り組むことに重点を置いています。医薬品産業は、患者の治療と地域社会の発展に不可欠であり、数多くの救命治療を提供し、雇用を創出し、世界経済に貢献しています。

ワクチン製造、発酵プロセス、バイオテクノロジーには、細菌やウイルスなど多くの生物製剤が使用されています。同市場は、巨大製薬会社、中堅特殊製薬会社、バーチャル製薬会社、ジェネリックメーカー、小規模バイオテクノロジー・バイオ医薬品企業など、多様な企業で構成されています。さらに、さまざまな治療製剤の開発・製剤化に携わる主要参入企業は、新規医薬品の開発と市場競合の維持のために、共同研究や提携に注力しています。

さらに、症状の予防や治療に対する需要の高まりに対応するため、複数の企業が新規医薬品の開発に取り組んでいます。例えば、2023年4月、F.ホフマン・ラ・ロシュ社は、2022年1月にFDAの承認を取得した同社の湿性加齢黄斑変性症治療Vabysmoが、2023年第1四半期に約5億米ドルの売上をもたらしたと発表しました。同治療の売上高は前年同期比500％以上増加し、多発性硬化症治療オクレバスや血友病治療ヘムリブラなどの競合薬を上回りました。さらに、NovartisAGは2023年7月、レクビオ（一般名：インクリシラン）について、心臓疾患のリスクが高いLDL-C高値患者の治療を追加する適応拡大承認を米国FDAから取得しました。

医薬品市場レポートハイライト

• 従来型医薬品（低分子）が2024年の売上高シェア54.74%で市場を独占。
• ブランドセグメントが医薬品市場を独占し、2024年の売上シェアは86.76%。
• 慢性疾患治療に対する需要の高まり、医薬品開発における技術進歩、医療アクセスの改善により、2024年の売上高シェアは86.76%で処方箋セグメントが市場を独占しました。
• がんセグメントは2024年に18.06％の売上シェアで市場を独占しました。
• 経口剤セグメントは、その利便性、患者のコンプライアンス、費用対効果により、2024年に57.53%の収益シェアでペプチド薬剤複合体市場を独占しました。
• ペプチド薬剤複合体市場は、成人市場が2024年に63.84％の売上シェアを占めました。
• 2024年の売上シェアは53.53%で、病院薬局部門がペプチド結合体市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 医薬品市場の変数、動向、範囲

• 親市場の展望
• 補助市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ドーパミン作動薬分析ツール
  • ポーターの分析
  • PESTEL分析
• パイプライン分析
  • フェーズ1
  • フェーズ2
  • フェーズ3

第4章 医薬品市場：医薬品別、推定・動向分析

• 医薬品市場：医薬品セグメントダッシュボード
• 医薬品市場：医薬品変動分析、100万米ドル、2024年と2030年
• 生物製剤とバイオシミラー（高分子）
  • モノクローナル抗体
  • ワクチン
  • 細胞・遺伝子治療
  • その他
• 従来型医薬品（低分子）

第5章 医薬品市場：タイプ別、推定・動向分析

• 医薬品市場：タイプセグメントダッシュボード
• 医薬品市場：タイプ変動分析、100万米ドル、2024年と2030年
• 処方薬
• 市販薬

第6章 医薬品市場：製品別、推定・動向分析

• 医薬品市場：製品セグメントダッシュボード
• 医薬品市場：製品変動分析、100万米ドル、2024年と2030年
• ブランド
• ジェネリック

第7章 医薬品市場： 疾病別、推定・動向分析

• 医薬品市場：疾患セグメントダッシュボード
• 医薬品市場：疾病変動分析、100万米ドル、2024年と2030年
• 心血管疾患
• がん
• 糖尿病
• 感染症
• 神経疾患
• 呼吸器疾患
• 自己免疫疾患
• 精神疾患
• 胃腸障害
• 女性の健康疾患
• 遺伝性疾患と稀少遺伝性疾患
• 皮膚疾患
• 肥満
• 腎臓疾患
• 肝臓の病気
• 血液疾患
• 目の状態
• 不妊症
• 内分泌障害
• アレルギー
• その他

第8章 医薬品市場： 投与経路別、推定・動向分析

• 医薬品市場：投与経路セグメントダッシュボード
• 医薬品市場：投与経路変動分析、100万米ドル、2024年と2030年
• 経口
  • 錠剤
  • カプセル
  • 懸濁液
  • その他
• 局所
• 非経口
  • 静脈内
  • 筋肉内
• 吸入
• その他

第9章 医薬品市場：年齢層別、推定・動向分析

• 医薬品市場：年齢層セグメントダッシュボード
• 医薬品市場：年齢層変動分析、100万米ドル、2024年と2030年
• 幼児と青少年
• 成人
• 高齢者

第10章 医薬品市場：流通チャネル別、推定・動向分析

• 医薬品市場：流通チャネルセグメントダッシュボード
• 医薬品市場：流通チャネル変動分析、100万米ドル、2024年と2030年
• 病院薬局
• 小売薬局
• その他

第11章 医薬品市場：地域別、推定・動向分析

• 医薬品市場シェア、地域別、2024年と2030年、100万米ドル
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第12章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業分類
• 参加者概要
• 製品ベンチマーク
• 企業市場シェア分析、2024年
• 企業プロファイル
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Takeda Pharmaceutical Co., Ltd.

第13章 結論

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 4 Global Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 5 Global Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 6 Global Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 7 Global Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 8 Global Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 9 Global Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 10 North America Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 11 North America Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 12 North America Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 13 North America Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 14 North America Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 15 North America Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 16 North America Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 17 North America Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 18 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 19 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 20 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 21 U.S. Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 22 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 23 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 24 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 25 Canada Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 26 Canada Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 27 Canada Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 28 Canada Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 29 Canada Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 30 Canada Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 31 Canada Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 32 Europe Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 33 Europe Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 34 Europe Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 35 Europe Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 36 Europe Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 37 Europe Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 38 Europe Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 39 Europe Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 40 Germany Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 41 Germany Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 42 Germany Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 43 Germany Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 44 Germany Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 45 Germany Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 46 Germany Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 47 UK Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 48 UK Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 49 UK Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 50 UK Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 51 UK Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 52 UK Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 53 UK Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 54 France Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 55 France Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 56 France Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 57 France Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 58 France Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 59 France Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 60 France Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 61 Italy Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 62 Italy Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 63 Italy Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 64 Italy Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 65 Italy Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 66 Italy Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 67 Italy Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 68 Spain Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 69 Spain Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 70 Spain Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 71 Spain Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 72 Spain Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 73 Spain Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 74 Spain Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 75 Asia Pacific Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 76 Asia Pacific Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 77 Asia Pacific Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 78 Asia Pacific Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 79 Asia Pacific Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 80 Asia Pacific Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 81 Asia Pacific Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 82 Asia Pacific Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 83 China Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 84 China Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 85 China Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 86 China Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 87 China Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 88 China Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 89 China Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 90 Japan Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 91 Japan Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 92 Japan Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 93 Japan Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 94 Japan Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 95 Japan Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 96 Japan Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 97 India Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 98 India Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 99 India Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 100 India Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 101 India Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 102 India Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 103 India Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 104 Middle East Pharmaceutical Market, By Country, 2018 - 2030 (USD Billion)
• Table 105 Middle East Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 106 Middle East Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 107 Middle East Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 108 Middle East Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 109 Middle East Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 110 Middle East Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 111 Middle East Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 112 Saudi Arabia Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 113 Saudi Arabia Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 114 Saudi Arabia Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 115 Saudi Arabia Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 116 Saudi Arabia Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 117 Saudi Arabia Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 118 Saudi Arabia Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 119 UAE Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 120 UAE Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 121 UAE Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 122 UAE Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 123 UAE Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 124 UAE Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 125 UAE Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)
• Table 126 Kuwait Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
• Table 127 Kuwait Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
• Table 128 Kuwait Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
• Table 129 Kuwait Pharmaceutical Market, By Diseases, 2018 - 2030 (USD Billion)
• Table 130 Kuwait Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
• Table 131 Kuwait Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
• Table 132 Kuwait Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Pharmaceutical Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Pharmaceutical market: Molecule type outlook and key takeaways
• Fig. 15 Pharmaceutical market: Molecule type movement analysis & market share 2024 & 2030
• Fig. 16 Biologics & biosimilars (large molecules) market, 2018 - 2030 (USD Billion)
• Fig. 17 Monoclonal Antibodies market, 2018 - 2030 (USD Billion)
• Fig. 18 Vaccines market, 2018 - 2030 (USD Billion)
• Fig. 19 Cell & Gene Therapy market, 2018 - 2030 (USD Billion)
• Fig. 20 Others market, 2018 - 2030 (USD Billion)
• Fig. 21 Conventional drugs (small molecules) market, 2018 - 2030 (USD Billion)
• Fig. 22 Pharmaceutical market: Product outlook and key takeaways
• Fig. 23 Pharmaceutical market: Product movement analysis & market share 2024 & 2030
• Fig. 24 Branded pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 25 Generics pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 26 Pharmaceutical market: Type outlook and key takeaways
• Fig. 27 Pharmaceutical market: Type movement analysis & market share 2024 & 2030
• Fig. 28 Prescription pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 29 OTC pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 30 Pharmaceutical market: Disease outlook and key takeaways
• Fig. 31 Pharmaceutical market: Disease movement analysis & market share 2024 & 2030
• Fig. 32 Cancer market, 2018 - 2030 (USD Billion)
• Fig. 33 Cardiovascular diseases market, 2018 - 2030 (USD Billion)
• Fig. 34 Diabetes market, 2018 - 2030 (USD Billion)
• Fig. 35 Infectious diseases market, 2018 - 2030 (USD Billion)
• Fig. 36 Neurological disorders market, 2018 - 2030 (USD Billion)
• Fig. 37 Respiratory diseases market, 2018 - 2030 (USD Billion)
• Fig. 38 Autoimmune diseases market, 2018 - 2030 (USD Billion)
• Fig. 39 Mental health disorders market, 2018 - 2030 (USD Billion)
• Fig. 40 Gastrointestinal diseases market, 2018 - 2030 (USD Billion)
• Fig. 41 Women's health diseases market, 2018 - 2030 (USD Billion)
• Fig. 42 Genetic and rare genetic diseases market, 2018 - 2030 (USD Billion)
• Fig. 43 Dermatological conditions market, 2018 - 2030 (USD Billion)
• Fig. 44 Obesity market, 2018 - 2030 (USD Billion)
• Fig. 45 Renal diseases market, 2018 - 2030 (USD Billion)
• Fig. 46 Liver conditions market, 2018 - 2030 (USD Billion)
• Fig. 47 Hemotological disorders market, 2018 - 2030 (USD Billion)
• Fig. 48 Eye conditions market, 2018 - 2030 (USD Billion)
• Fig. 49 Infertility conditions market, 2018 - 2030 (USD Billion)
• Fig. 50 Endocrine disorders market, 2018 - 2030 (USD Billion)
• Fig. 51 Allergies market, 2018 - 2030 (USD Billion)
• Fig. 52 Other diseases market, 2018 - 2030 (USD Billion)
• Fig. 53 Pharmaceutical market: Route of administration outlook and key takeaways
• Fig. 54 Pharmaceutical market: Route of administration movement analysis & market share 2024 & 2030
• Fig. 55 Oral pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 56 Tablets pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 57 Capsules pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 58 Suspensions pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 59 Others formulation pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 60 Topical pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 61 Parenteral pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 62 Intravenous market, 2018 - 2030 (USD Billion)
• Fig. 63 Intramuscular market, 2018 - 2030 (USD Billion)
• Fig. 64 Inhalations pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 65 Others pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 66 Pharmaceutical market: Age group outlook and key takeaways
• Fig. 67 Pharmaceutical market: Age group movement analysis & market share 2024 & 2030
• Fig. 68 Children & Adolescents pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 69 Adults pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 70 Geriatric pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 71 Pharmaceutical market: Distribution Channel outlook and key takeaways
• Fig. 72 Pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2030
• Fig. 73 Hospital Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 74 Retail Pharmacy pharmaceutical market, 2018 - 2030 (USD Billion)
• Fig. 75 Others pharmaceutical market, 2018 - 2030 (USD Billion
• Fig. 76 Regional Outlook, 2024 & 2030
• Fig. 77 Regional Market Dashboard
• Fig. 78 Regional Market Place: Key Takeaways
• Fig. 79 North America
• Fig. 80 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 81 U.S. Key Country Dynamics
• Fig. 82 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 83 Canada Key Country Dynamics
• Fig. 84 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 85 Mexico Key Country Dynamics
• Fig. 86 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 87 Europe
• Fig. 88 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 89 UK Key Country Dynamics
• Fig. 90 UK Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 91 Germany Key Country Dynamics
• Fig. 92 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 93 France Key Country Dynamics
• Fig. 94 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 95 Italy Key Country Dynamics
• Fig. 96 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 97 Spain Key Country Dynamics
• Fig. 98 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 99 Denmark Key Country Dynamics
• Fig. 100 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 101 Sweden Key Country Dynamics
• Fig. 102 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 103 Norway Key Country Dynamics
• Fig. 104 Norway Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 105 Asia Pacific
• Fig. 106 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 107 Japan Key Country Dynamics
• Fig. 108 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 109 China Key Country Dynamics
• Fig. 110 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 111 India Key Country Dynamics
• Fig. 112 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 113 Australia Key Country Dynamics
• Fig. 114 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 115 Thailand Key Country Dynamics
• Fig. 116 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 117 South Korea Key Country Dynamics
• Fig. 118 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 119 Latin America
• Fig. 120 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 121 Brazil Key Country Dynamics
• Fig. 122 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 123 Argentina Key Country Dynamics
• Fig. 124 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 125 MEA
• Fig. 126 MEA Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 127 South Africa Key Country Dynamics
• Fig. 128 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 129 Saudi Arabia Key Country Dynamics
• Fig. 130 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 131 UAE Key Country Dynamics
• Fig. 132 UAE Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 133 Kuwait Key Country Dynamics
• Fig. 134 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Billion)
• Fig. 135 Strategy Mapping

Pharmaceutical Market Growth & Trends:

The global pharmaceutical market size is estimated to reach USD 2,350.43 billion by 2030, registering to grow at a CAGR of 6.12% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023, F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022, brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights:

• The Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
• The branded segment dominated the pharmaceutical market with a revenue share of 86.76% in 2024.
• The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access.
• The cancer segment dominated the market with a revenue share of 18.06% in 2024.
• The oral segment dominated the peptide drug conjugates market with a revenue share of 57.53% in 2024 due to its convenience, patient compliance, and cost-effectiveness.
• The adults segment dominated the peptide drug conjugates market with a revenue share of 63.84% in 2024.
• The hospital pharmacy segment dominated the peptide drug conjugates market with a revenue share of 53.53% in 2024

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Advancement in therapeutics and robust product pipeline
    • 3.3.1.2. Rise in pharmaceutical r&d spending
    • 3.3.1.3. Rise in pharmaceutical r&d spending
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Patent expiration of key market drugs
    • 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
    • 3.3.2.3. Stringent regulatory scenario
• 3.4. Dopamine Agonist Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Pharmaceutical Market: By Drug Estimates & Trend Analysis

• 4.1. Pharmaceutical Market: Drug Segment Dashboard
• 4.2. Pharmaceutical Market: By Drug Movement Analysis, USD Million, 2024 & 2030
• 4.3. Biologics & Biosimilars (Large Molecules)
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Monoclonal Antibodies
    • 4.3.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.3. Vaccines
    • 4.3.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.4. Cell & Gene Therapy
    • 4.3.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3.5. Others
    • 4.3.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Conventional Drugs (Small Molecules)
  • 4.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Market: Type Estimates & Trend Analysis

• 5.1. Pharmaceutical Market: Type Segment Dashboard
• 5.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
• 5.3. Prescription
  • 5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. OTC
  • 5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pharmaceutical Market: Product Estimates & Trend Analysis

• 6.1. Pharmaceutical Market: Product Segment Dashboard
• 6.2. Pharmaceutical Market: By Product Movement Analysis, USD Million, 2024 & 2030
• 6.3. Branded
  • 6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Generics
  • 6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pharmaceutical Market: Disease Estimates & Trend Analysis

• 7.1. Pharmaceutical Market: Disease Segment Dashboard
• 7.2. Pharmaceutical Market: By Disease Movement Analysis, USD Million, 2024 & 2030
• 7.3. Cardiovascular diseases
  • 7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Cancer
  • 7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Diabetes
  • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Infectious diseases
  • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Neurological disorders
  • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Respiratory diseases
  • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Autoimmune diseases
  • 7.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Mental health disorders
  • 7.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.11. Gastrointestinal disorders
  • 7.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.12. Women's Health Diseases
  • 7.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.13. Genetic and Rare genetic diseases
  • 7.13.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.14. Dermatological conditions
  • 7.14.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.15. Obesity
  • 7.15.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.16. Renal diseases
  • 7.16.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.17. Liver conditions
  • 7.17.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.18. Hematological disorders
  • 7.18.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.19. Eye conditions
  • 7.19.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.20. Infertility conditions
  • 7.20.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.21. Endocrine disorders
  • 7.21.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.22. Allergies
  • 7.22.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.23. Others
  • 7.23.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

• 8.1. Pharmaceutical Market: Route of Administration Segment Dashboard
• 8.2. Pharmaceutical Market: By Route of Administration Movement Analysis, USD Million, 2024 & 2030
• 8.3. Oral
  • 8.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. Tablets
  • 8.3.3. Capsules
  • 8.3.4. Suspensions
  • 8.3.5. Other
• 8.4. Topical
  • 8.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Parenteral
  • 8.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Intravenous
  • 8.5.3. Intramuscular
• 8.6. Inhalations
  • 8.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Other Routes of Administration
  • 8.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Pharmaceutical Market: Age Group Estimates & Trend Analysis

• 9.1. Pharmaceutical Market: Age Group Segment Dashboard
• 9.2. Pharmaceutical Market: By Age Group Movement Analysis, USD Million, 2024 & 2030
• 9.3. Children & Adolescents
  • 9.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Adults
  • 9.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Geriatric
  • 9.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis

• 10.1. Pharmaceutical Market: Distribution Channel Segment Dashboard
• 10.2. Pharmaceutical Market: By Distribution Channel Movement Analysis, USD Million, 2024 & 2030
• 10.3. Hospital Pharmacy
  • 10.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.4. Retail Pharmacy
  • 10.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 10.5. Others
  • 10.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Pharmaceutical Market: Regional Estimates & Trend Analysis

• 11.1. Pharmaceutical Market Share, By Region, 2024 & 2030, USD Million
• 11.2. North America
  • 11.2.1. North America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Regulatory Framework
    • 11.2.2.4. Reimbursement Framework
    • 11.2.2.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Regulatory Framework
    • 11.2.3.4. Reimbursement Framework
    • 11.2.3.5. U.S. Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.2.4. Mexico
    • 11.2.4.1. Key Country Dynamics
    • 11.2.4.2. Target Disease Prevalence
    • 11.2.4.3. Regulatory Framework
    • 11.2.4.4. Reimbursement Framework
    • 11.2.4.5. Mexico Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.2. UK
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Regulatory Framework
    • 11.3.2.4. Reimbursement Framework
    • 11.3.2.5. Uk Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.3. Germany
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Regulatory Framework
    • 11.3.3.4. Reimbursement Framework
    • 11.3.3.5. Germany Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Regulatory Framework
    • 11.3.4.4. Reimbursement Framework
    • 11.3.4.5. France Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Regulatory Framework
    • 11.3.5.4. Reimbursement Framework
    • 11.3.5.5. Italy Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Regulatory Framework
    • 11.3.6.4. Reimbursement Framework
    • 11.3.6.5. Spain Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Regulatory Framework
    • 11.3.7.4. Reimbursement Framework
    • 11.3.7.5. Denmark Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Regulatory Framework
    • 11.3.8.4. Reimbursement Framework
    • 11.3.8.5. Sweden Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Regulatory Framework
    • 11.3.9.4. Reimbursement Framework
    • 11.3.9.5. Norway Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Regulatory Framework
    • 11.4.2.4. Reimbursement Framework
    • 11.4.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Regulatory Framework
    • 11.4.3.4. Reimbursement Framework
    • 11.4.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Regulatory Framework
    • 11.4.4.4. Reimbursement Framework
    • 11.4.4.5. India Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.5. Australia
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Regulatory Framework
    • 11.4.5.4. Reimbursement Framework
    • 11.4.5.5. Australia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.6. South Korea
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Regulatory Framework
    • 11.4.6.4. Reimbursement Framework
    • 11.4.6.5. South Korea Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Regulatory Framework
    • 11.4.7.4. Reimbursement Framework
    • 11.4.7.5. Thailand Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Regulatory Framework
    • 11.5.2.4. Reimbursement Framework
    • 11.5.2.5. Japan Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.5.3. Argentina
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Regulatory Framework
    • 11.5.3.4. Reimbursement Framework
    • 11.5.3.5. China Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 11.6. Middle East and Africa
  • 11.6.1. Middle East and Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Regulatory Framework
    • 11.6.2.4. Reimbursement Framework
    • 11.6.2.5. South Africa Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Regulatory Framework
    • 11.6.3.4. Reimbursement Framework
    • 11.6.3.5. Saudi Arabia Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Regulatory Framework
    • 11.6.4.4. Reimbursement Framework
    • 11.6.4.5. UAE Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Regulatory Framework
    • 11.6.5.4. Reimbursement Framework
    • 11.6.5.5. Kuwait Pharmaceutical Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Recent Developments & Impact Analysis by Key Market Participants
• 12.2. Company Categorization
• 12.3. Participant Overview
• 12.4. Financial Performance
• 12.5. Product Bench Marking
• 12.6. Company Market Share Analysis, 2024
• 12.7. Company Profiles
  • 12.7.1. F. Hoffmann-La Roche Ltd
    • 12.7.1.1. Participant's Overview
    • 12.7.1.2. Financial Performance
    • 12.7.1.3. Product Benchmarking
    • 12.7.1.4. Recent Developments/ Strategic Initiatives
  • 12.7.2. Novartis AG
    • 12.7.2.1. Participant's Overview
    • 12.7.2.2. Financial Performance
    • 12.7.2.3. Product Benchmarking
    • 12.7.2.4. Recent Developments/ Strategic Initiatives
  • 12.7.3. AbbVie Inc.
    • 12.7.3.1. Participant's Overview
    • 12.7.3.2. Financial Performance
    • 12.7.3.3. Product Benchmarking
    • 12.7.3.4. Recent Developments/ Strategic Initiatives
  • 12.7.4. Johnson & Johnson Services, Inc.
    • 12.7.4.1. Participant's Overview
    • 12.7.4.2. Financial Performance
    • 12.7.4.3. Product Benchmarking
    • 12.7.4.4. Recent Developments/ Strategic Initiatives
  • 12.7.5. Merck & Co., Inc.
    • 12.7.5.1. Participant's Overview
    • 12.7.5.2. Financial Performance
    • 12.7.5.3. Product Benchmarking
    • 12.7.5.4. Recent Developments/ Strategic Initiatives
  • 12.7.6. Pfizer Inc.
    • 12.7.6.1. Participant's Overview
    • 12.7.6.2. Financial Performance
    • 12.7.6.3. Product Benchmarking
    • 12.7.6.4. Recent Developments/ Strategic Initiatives
  • 12.7.7. Bristol-Myers Squibb Company
    • 12.7.7.1. Participant's Overview
    • 12.7.7.2. Financial Performance
    • 12.7.7.3. Product Benchmarking
    • 12.7.7.4. Recent Developments/ Strategic Initiatives
  • 12.7.8. Sanofi
    • 12.7.8.1. Participant's Overview
    • 12.7.8.2. Financial Performance
    • 12.7.8.3. Product Benchmarking
    • 12.7.8.4. Recent Developments/ Strategic Initiatives
  • 12.7.9. GlaxoSmithKline plc.
    • 12.7.9.1. Participant's Overview
    • 12.7.9.2. Financial Performance
    • 12.7.9.3. Product Benchmarking
    • 12.7.9.4. Recent Developments/ Strategic Initiatives
  • 12.7.10. AstraZeneca
    • 12.7.10.1. Participant's Overview
    • 12.7.10.2. Financial Performance
    • 12.7.10.3. Product Benchmarking
    • 12.7.10.4. Recent Developments/ Strategic Initiatives
  • 12.7.11. Takeda Pharmaceutical Co., Ltd.
    • 12.7.11.1. Participant's Overview
    • 12.7.11.2. Financial Performance
    • 12.7.11.3. Product Benchmarking
    • 12.7.11.4. Recent Developments/ Strategic Initiatives

Chapter 13. Conclusion